Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

CRISPR hope for kids with sickle cell: One-Time treatment may stop pain crises

NCT ID NCT05329649

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times

Summary

This study tests a one-time gene-editing treatment (CTX001) in children with severe sickle cell disease who cannot take hydroxyurea. The treatment uses the child's own blood stem cells, modified with CRISPR-Cas9, to produce healthy red blood cells. The goal is to prevent severe pain crises and hospital stays for at least 12 months. The study is in Phase 3 and involves 13 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOGLOBINOPATHIES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica

    Rome, Italy

  • Levine Children's Hospital - Hematology

    Charlotte, North Carolina, 28203, United States

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

  • St.Mary's Hospital - Haematology Dept

    London, United Kingdom

  • The Children's Hospital of Philadelphia - Hematology

    Philadelphia, Pennsylvania, 19104, United States

  • TriStar Medical Group Children's Specialists - Pediatric Oncology

    Nashville, Tennessee, 37203, United States

  • University Hospital Duesseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology

    Düsseldorf, Germany

Conditions

Explore the condition pages connected to this study.